CN101835759A - 芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途 - Google Patents

芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途 Download PDF

Info

Publication number
CN101835759A
CN101835759A CN200880112882A CN200880112882A CN101835759A CN 101835759 A CN101835759 A CN 101835759A CN 200880112882 A CN200880112882 A CN 200880112882A CN 200880112882 A CN200880112882 A CN 200880112882A CN 101835759 A CN101835759 A CN 101835759A
Authority
CN
China
Prior art keywords
disorder
subject
adenosine
disease
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880112882A
Other languages
English (en)
Chinese (zh)
Inventor
B·C·舒克
P·F·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101835759A publication Critical patent/CN101835759A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880112882A 2007-10-24 2008-10-17 芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途 Pending CN101835759A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24
US60/982247 2007-10-24
PCT/US2008/080256 WO2009055308A1 (en) 2007-10-24 2008-10-17 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
CN101835759A true CN101835759A (zh) 2010-09-15

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880112882A Pending CN101835759A (zh) 2007-10-24 2008-10-17 芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途

Country Status (12)

Country Link
US (1) US8017614B2 (https=)
EP (1) EP2217575A1 (https=)
JP (1) JP2011500819A (https=)
CN (1) CN101835759A (https=)
AR (1) AR069009A1 (https=)
AU (1) AU2008317034A1 (https=)
CL (1) CL2008003131A1 (https=)
PA (1) PA8801501A1 (https=)
PE (1) PE20091344A1 (https=)
TW (1) TW200934493A (https=)
UY (1) UY31420A1 (https=)
WO (1) WO2009055308A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ATE429421T1 (de) 2003-10-03 2009-05-15 Ortho Mcneil Pharm Inc Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten

Also Published As

Publication number Publication date
EP2217575A1 (en) 2010-08-18
US8017614B2 (en) 2011-09-13
WO2009055308A1 (en) 2009-04-30
AR069009A1 (es) 2009-12-23
TW200934493A (en) 2009-08-16
UY31420A1 (es) 2009-04-30
US20090111827A1 (en) 2009-04-30
JP2011500819A (ja) 2011-01-06
CL2008003131A1 (es) 2010-02-19
PE20091344A1 (es) 2009-09-24
PA8801501A1 (es) 2009-05-15
AU2008317034A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2380891B1 (de) Substituierte Piperidino-Dihydrothienopyrimidine
US6589958B1 (en) Isoxazolo [4,5-d] pyrimidines as CRF antagonists
TWI547494B (zh) 作為激酶抑制劑之胺基喹唑啉類
US20080139551A1 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
CN116648248A (zh) 芳香化合物、含其的药物组合物及其应用
TWI592417B (zh) 胺基喹唑啉激酶抑制劑之前藥
TW201326138A (zh) 犬尿胺酸－３－單氧化酶抑制劑、其醫藥組成物及其使用方法
CN101835759A (zh) 芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途
US20100093702A1 (en) METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2220053B1 (en) Arylindenopyrimidines and their use as adenosine a2a receptor antagonists
CN117836270A (zh) Usp30抑制剂及其用途
RS20060237A (sr) Arilindenopiridini i arilindenopirimidini i njihova upotreba kao antagonista adenozin a2a receptora
US20100093764A1 (en) AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
KR20190040030A (ko) 암 치료용 티오히단토인 안드로겐 수용체 길항제
US20060154949A1 (en) Arylindenopyridines and related therapeutic and prophylactic methods
US20100093714A1 (en) AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20110105541A1 (en) ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2010313574A1 (en) 2-amino-9-[4-(4-methoxy-phenoxy) - piperid in -1-yl] -4-phenyl-indeno [1,2-d] pyrimidin -5 -one and its use as a highly selective adenosine A2A receptor antagonist
US20050239782A1 (en) Arylindenopyridines and related therapeutic and prophylactic methods
MX2011003964A (es) Tieno[2,3-d]pirimidinas sustituidas con heteroarilo y felino y su uso como antagonistas de receptores de adenosina a2a.
KR20060108652A (ko) 아릴린데노피리딘과 아릴린데노피리딘 및 Ａ2ａ 수용체길항제로서 이들의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100915